Cite
HARVARD Citation
Sundar, R. et al. (2019). Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer. Annals of oncology. pp. 424-430. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Sundar, R. et al. (2019). Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer. Annals of oncology. pp. 424-430. [Online].